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Abstract 
Background: Young patients (<50 years) exhibit specific characteristics in chronic 
heart failure (HF), but their phenotype in acute heart failure (AHF) is not well 
described.  
Methods and Results: 2033 patients of the PROTECT trial were divided into two 
groups: young patients (≤50 years) and older patients (>50 years). Biomarkers from 
different pathophysiological domains were available in 1266 patients. Patients were 
compared with regard to clinical characteristics, biomarker profiles, and in-hospital 
(worsening renal function [WRF] and decongestion) and post-discharge (180-day 
survival) outcome. Young patients (n=121) were mostly men, had fewer comorbidities 
with better renal function, and more often had a reduced ejection fraction. At 
admission, young patients were more likely to have jugular venous distension, but 
less rales and dyspnea compared with older patients. During hospitalization, young 
patients received higher loop diuretic doses, and were decongested earlier than older 
patients. WRF occurred less frequently in young patients (5.9% vs. 13.3%, p=0.020) 
and they were more often discharged alive. At 180 days, the mortality of young 
patients was lower than that of the older patients (9.9% vs. 18.1, p=0.021). Biomarker 
levels indicative of inflammation and renal damage were lower in the young, although 
they exhibited higher BNP levels than older patients. 
Conclusions: Despite use of higher diuretic doses, young patients with AHF less 
often developed WRF during hospitalization and had better outcomes than older 
patients. Differences in biomarker levels between the age groups suggest distinct 
underlying pathophysiologies. 
https://clinicaltrials.gov numbers NCT00328692 and NCT00354458 
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Introduction 
 
The incidence of heart failure (HF) increases with age, and HF is a common disease 
of elderly patients[1,2]. Data on HF in patients aged less than 50 years are 
limited[1,3,4]. Three studies reported on the characteristics and clinical outcome of 
younger patients with chronic HF, which indicate a distinct phenotype, typically 
comprising non-ischemic etiology, more severe left ventricular dysfunction and less 
concomitant comorbidities compared to older patients[5–10].  
Most studies in AHF focus on the elderly[3,4]. However, the specific 
characteristics and the clinical outcome of young patients who are hospitalized for 
acute HF (AHF) are currently not well described. Therefore, we sought to 
characterize differences in baseline characteristics, management, and clinical 
outcomes of young patients compared to older patients hospitalized for AHF. In 
addition, we studied biomarkers from different pathophysiological domains in young 
versus older patients to gain insight in underlying differences in pathophysiology.  
 
Methods. 
Study design and population 
The Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor 
Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart 
Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal 
FuncTion (PROTECT) was a multicenter, randomized, placebo-controlled trial for 
which the design and primary results have previously been published[11–13]. In brief, 
PROTECT included 2033 patients hospitalized for AHF with impaired renal function 
(estimated creatinine clearance between 20 and 80ml/min), signs and symptoms of 
fluid overload, concomitant dyspnea, NYHA III–IV symptoms, systolic blood pressure 
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≥ 95mmHg, who required i.v. diuretic therapy. Overall results of the PROTECT trial 
were neutral and have been previously reported[11,13]. This study complied with the 
Declaration of Helsinki and was approved by local Ethics Committees. All patients 
provided written informed consent. 
 
Definitions and endpoints 
Patients younger than or equal to 50 years were classified as “young”; whereas the 
remainder of patients was referred to as older (>50 years) in accordance with 
previous publications [3,5].  HF with preserved ejection fraction (HFpEF) was defined 
as left ventricular ejection fraction (LVEF) >45% based on available 
echocardiographic data in 976 patients. The total diuretic dose through day 4 was 
defined as the sum of the daily oral (p.o.) and intravenous (i.v.) diuretic doses, 
weighing the effects of i.v. loop diuretics with the factor 1 and those of p.o. loop 
diuretics with the factor 0.5. 
 The primary and secondary endpoints of PROTECT have previously been 
described in detail[11,12]. We assessed the primary pre-specified trichotomous 
endpoint, a classification of therapy response into ‘‘success’’ (Improvement in 
dyspnea (7-point Likert scale) without treatment failure), ‘‘failure’’ (Death or 
readmission for heart failure to day 7, worsening heart failure symptoms from >1 to 7 
days after treatment, requiring rescue therapy, or persistent renal impairment) or 
‘‘unchanged’’ across age groups. Additionally, the secondary end points 60-day 
death and hospitalizations, 60-day death or rehospitalization, 60-day death or HF 
rehospitalization, 60-day HF rehospitalization, 60-day death, cardiovascular or renal 
rehospitalization and 180-day mortality were analyzed. An independent endpoint 
committee adjudicated all rehospitalizations through day 60 and deaths through day 
180. 
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Biomarkers 
Of the 2033 patients in PROTECT, 1266 patients had complete biomarker data 
available at baseline. Forty-eight biomarkers were assessed for the present analysis. 
Blood urea nitrogen (BUN) and creatinine, were measured in a central laboratory 
(ICON Laboratories, Farmingdale, New York). A panel of 26 biomarkers was 
measured by Alere Inc., San Diego, CA, USA. Galectin-3, myeloperoxidase and 
neutrophil gelatinase-associated lipocalin (NGAL) were measured using sandwich 
enzyme-linked immonsorbent assays (ELISA) on a microtiter plate; angiogenin and 
C-reactive protein (CRP) were measured using competitive ELISAs on a Luminex® 
platform; D-dimer, endothelial cell-selective adhesion molecule, growth differentiation 
factor 15 (GDF-15), lymphotoxin beta receptor, mesothelin, neuropilin, N-terminal pro 
C-type natriuretic peptide (NT-proCNP), osteopontin, procalcitonin, pentraxin-3, 
periostin, polymeric immunoglobulin receptor, pro-adrenomedullin (proADM), 
prosaposin B, receptor for advanced glycationendproducts, soluble ST-2 (sST-2), 
syndecan-1, tumor necrosis factor alpha receptor 1 (TNFR-1), Troy, vascular 
endothelial growth receptor 1 (VEGFR-1) and WAP four-disulphide core domain 
protein HE4 were measured using sandwich ELISAs on a Luminex® platform. 
Immunoassays to PCT, proADM, Galectin-3 and ST2 were developed by Alere. 
These research assays have not been standardized to the commercialized assays 
used in research or in clinical use and the extent to which each Alere assay 
correlates with the commercial assay is not fully characterized (supplementary table 
1).  
 Additionally, a panel of four biomarkers – Endothelin-1 (ET-1), Interleukin-
6 (IL-6), Kidney Injury Molecule 1 (KIM-1) and cardiac specific Troponin I (cTnI) was 
measured in frozen plasma samples collected at baseline using high sensitive single 
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molecule counting (SMC™) technology (RUO, Erenna® Immunoassay System, 
Singulex Inc., Alameda, CA, USA) (see supplementary methods for details). N-
terminal pro-brain natriuretic peptide (NT-proBNP) was measured during screening 
using commercial assays available at the study centers or a point of care device 
provided to study sites when needed.  
 
Statistical analyses  
Summary baseline statistics for continuous variables are presented as mean with 
standard deviation or median with interquartile range as appropriate, and proportions 
for categorical variables.  
 Equality of the means of continuous, normally distributed variables across age 
groups were tested using Students’ t-test. Equality of ranks of continuous, skewed 
distributed variables across age groups were tested using the Mann-Whitney-U test. 
Independent distributions of frequencies in categorical variables between age groups 
were tested using Pearson's chi-squared test.  
 Statistical analyses were performed using STATA (version 13.1. STATA Corp. 
College Station. TX. USA). Two-sided P-values < 0.05 were considered statistically 
significant. 
 
Results  
Baseline characteristics. 
Table 1 shows the baseline demographic and clinical characteristics in both age 
groups.  
 A total of 121 (6%) patients in PROTECT were younger than 50 years, with a 
mean age of 43.9±6.4 years. Young patients were predominantly men, had a higher 
body mass index and higher estimated glomerular filtration rate, while having lower 
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left ventricular ejection fraction, lower systolic blood pressure and higher heart rate 
compared to older patients. They had lower rates of ischemic heart disease, atrial 
fibrillation, hypertension, stroke and peripheral vascular disease. However, the 
proportion of patients with a history of HF and hospitalization for HF during the 
previous year was higher in young patients.  
Details on medication, non-pharmacological therapy and treatment response 
during hospitalization are presented in table 2 and figure 1. Younger patients were 
more often treated with beta-blockers and mineral receptor antagonists, and less 
often with nitrates and calcium channel blockers. Additionally, mineral receptor 
antagonists were more often initiated and/or their doses were more often increased 
in young patients during hospitalization (figure 1). 
  
Outcomes 
Young patients were treated with higher IV and oral loop diuretic doses during 
hospitalization (table 2) than older patients. From admission to day 4, young patients 
showed the higher absolute weight loss, while diuretic response was similar 
compared to the older patients. Additionally, young HF patients showed lower rates 
of worsening renal function (WRF) (5.8% vs. 15.3%, p=0.004) (table 2). 
The primary pre-specified trichotomous endpoint did not differ across the age 
groups, albeit that young AHF patients were more frequently readmitted for HF, but 
less often showed serum creatinine increase and persistent renal impairment (table 
3). Young patients had lower 180-day mortality (9.9% vs. 18.1%, p=0.021) (table 3). 
HF / pump failure was the most frequent cause of death in young patients (table 3).  
 
Biomarker profiles 
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The levels of biomarkers at baseline are shown in table 4. Younger patients had 
lower levels of IL-6, PIGR, TNFR1A, WAP4C, galectin 3, mesothelin, LTBR, ESAM-
1, BUN, NGAL and KIM-1. In contrast, VEGFR1 and angiogenin were higher in 
young patients. 
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Discussion 
This study provides a comprehensive overview of clinical characteristics, in-hospital 
management, clinical outcomes and biomarker differences between young and older 
AHF patients. Young patients had distinct signs and symptoms of acute HF at 
hospital admission compared to the elderly. Furthermore, during hospitalization 
young patients were treated with higher diuretic doses, which led to a similar diuretic 
response. However, diuretic treatment was accompanied by less WRF during 
hospitalization. Biomarker levels significantly differed between both age groups. 
Compared to older patients, the young AHF patients mainly exhibited lower levels of 
biomarkers indicative of inflammation and renal damage.  
Overall, young patients showed a typical pattern of signs and symptoms of 
AHF at admission, which confirms previous reports in a chronic setting [5,6]. They 
less frequently had rales, dyspnea and angina, but a higher jugular venous pressure. 
Young patients with AHF had a more favorable clinical profile with less comorbidities, 
less ischemic etiology and less renal dysfunction than older patients, as previously 
reported in patients with chronic heart failure[5]. Although several other studies 
explored the clinical features of acute heart failure and their relationship with patient 
age, these studies primarily focused on the characteristics of elderly patients, rarely 
included patients younger than 50 years of age and are limited to only few standard 
blood biomarkers [4,7,14]. Importantly, Metra et al. previously analyzed the influence 
of age on patient characteristics and outcome. He found that with increasing age, 
patients more often exhibited characteristics such as female sex, hypertension, atrial 
fibrillation, and higher left ventricular ejection fraction. This was paralleled by 
independent increased risk of adverse 30- and 180-day outcomes [4].   
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In our study, young patients had higher estimated glomerular filtration rates at 
admission, and during hospitalization for AHF they experienced less persistent WRF. 
The less impaired renal function at baseline is typical for younger compared to older 
patients with acute heart failure and could in part explain that during diuretic therapy, 
young patients less frequently developed WRF than older HF patients [15]. Young 
HF patients were treated with higher doses of diuretics and showed more weight 
loss. Interestingly, a recent sub-analysis of the EVEREST trial showed that a worse 
congestion status during AHF hospitalization was associated with worse 
outcomes[16]. The data from this study suggest that the better diuretic response of 
the young patients in our study is related to a better renal function, which translates 
to more favorable outcomes with regard to the primary endpoint. 
We used biomarkers to better characterize acute heart failure in the young. 
Overall, young patients had lower levels of inflammatory markers. There is a clear 
pattern of lower median values of inflammatory biomarkers in the younger patients as 
opposed to older patients, although only few biomarkers, such as IL-6, TNFR1A, 
LTBR and WAP4C, reached the statistical significance level. The lower level of 
inflammation can potentially be explained by the fact that younger patients suffer 
from less comorbidities and more often had HFrEF[17–19]. It has been hypothesized 
that comorbidities, such as COPD and aging, contribute to a general pro-
inflammatory state, which is accompanied by higher levels of inflammation markers 
and more prevalent in the elderly[20,21]. This also holds true for our data, where 
young AHF patients had more HFrEF and fewer comorbidities compared to their 
elder peers. Notably, this effect can be detected despite the higher body mass index 
in the younger patients. Although it is known that obesity should actually be 
associated with an increase in biomarkers of inflammation, our study shows that the 
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level of inflammation in younger patients with acute decompensated heart failure is 
lower than that of older patients. 
Furthermore, biomarkers associated with poor renal function (BUN, NGAL, 
KIM-1, galectin-3) were lower in younger patients[22–26]. This correlates with the 
finding that younger patients overall had a better renal function at admission and 
were less often subject to WRF during hospitalization.  
 Angiogenesis markers had a heterogeneous distribution across both age 
groups. Levels of endothelial cell-selective adhesion molecule (esam-1), an 
endothelial dysfunction marker, were found to be lower in the young; this likely 
reflects that the young less often had a history of myocardial infarction and ischemic 
heart disease[27]. Indeed, higher levels of esam-1 were previously found to be 
associated with arteriosclerosis[27]. Additionally, higher esam-1 levels were shown to 
be independently associated with impaired renal function[28]. Furthermore, 
mesothelin levels were previously found to be higher in patients with impaired renal 
function, which is in accordance with our results[29]. Angiogenin and VEGFR1, which 
had the highest levels in young patients, were linked to angiogenesis and 
revascularization[30–33]. Both markers are pathophysiologically involved in vascular 
repair and cardiac remodeling, both of which are etiological factors for the 
development of HFrEF. Angiogenesis is impaired in the elderly, possibly also 
contributing to the lower levels of these two biomarkers in the older patients[33].  
 The main clinical implication of our findings is that younger patients with AHF 
are a distinct subgroup. Young patients can be decongested more aggressively at 
lower risk of worsening renal function with anticipated better outcomes than older 
patients with AHF. Biomarkers reflect a characteristic pattern of pathophysiological 
processes in young patients. 
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Limitations 
A limitation of our study is the relatively small sample size of patients’ younger than 
50 years of age and the misbalance compared to the much larger group of older 
patients, which could introduce bias to the detected differences. Additionally, as a 
post hoc study, a possible selection bias may be present. Lastly, the main PROTECT 
trial was not primarily designed to assess mortality.  
 
Conclusions. 
Despite being treated with higher dosage of diuretic therapy, young AHF patients 
develop less WRF compared to their older peers during hospitalization.  Clinically, 
young AHF patients in the PROTECT dataset had lower LVEFs, fewer comorbidities 
and a lower rate of HFpEF. Biomarkers potentially reflect these pathophysiological 
differences between young and older AHF patients.   
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Figure Legends 
Figure 1: Stacked bar charts showing medication dose changes for ace-inhibitors, 
beta blockers and mineral receptor inhibitors.  
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Table 1. Baseline differences of clinical characteristics across age groups  
  ≤50 >50 p-value 
N 121 (6%) 1912 (94%)   
Demographics       
Age, years, mean ± SD 43.9 ± 6.4 71.8 ± 9.6 <0.001 
Male sex, (%) 83.5 66.1 <0.001 
BMI, kg/m2, mean ± SD 31.0 ± 9.3 28.7 ± 5.9 <0.001 
eGFR, mL/min/1.73 m2, mean ± SD 63.2 ± 24.8 47.6 ± 18.6 <0.001 
NYHA class, (%)     0.470 
   I/II 15.7 18.0 
    III 56.5 50.7  
   IV 27.8 31.3   
LVEF,%, median (IQR) 25 (20, 35) 30 (23, 40) <0.001 
HFpEF (EF >45), (%) 7.0 16.4 0.038 
Systolic BP, mmHg, mean ± SD 116.2 ± 16.6 124.8 ± 17.6 <0.001 
Diastolic BP, mmHg, mean ± SD 74.3 ± 12.4 73.7 ± 11.8 0.580 
20 
Heart rate, b.p.m. mean ± SD 84.9 ± 14.0 79.8 ± 15.5 <0.001 
Medical history       
Mitral regurgitation, (%) 38.8 33.6 0.230 
Heart failure (HF), (%) 95.0 94.8 0.900 
Hospitalization for HF previous year,(%) 63.6 48.4 0.001 
HF hospitalizations, median (IQR) 2.0 (1.0, 3.0) 1.0 (1.0, 2.0) 0.043 
Ischemic heart disease, (%) 30.6 72.3 <0.001 
Myocardial infarction, (%) 25.6 50.8 <0.001 
Hypertension, (%) 63.6 80.4 <0.001 
Stroke or PVD, (%) 7.4 19.0 0.001 
COPD or asthma, (%) 14.0 20.2 0.100 
Diabetes mellitus, (%) 29.2 46.4 <0.001 
History of Atrial Fibrillation/Flutter, (%) 28.3 56.3 <0.001 
AICD, (%) 29.8 15.1 <0.001 
Pacemaker, (%) 6.7 12.6 0.054 
Medication prior to admission, (%)       
Beta-blockers, (%) 86.0 75.6 0.010 
ACE-I/ARB, (%) 79.3 75.4 0.330 
21 
MRA, (%) 58.7 42.8 <0.001 
Digoxin, (%) 28.1 28.1 0.990 
Nitrates, (%) 10.7 26.9 <0.001 
CCBs, (%) 4.1 14.2 0.002 
Presenting signs & symptoms       
Orthopnea, (%) 81.9 83.9 0.580 
Dyspnea at rest (NYHA IV), (%) 47.4 57.6 0.031 
Angina pectoris, (%) 8.3 22.9 <0.001 
Edema, (%) 24.8 27.8 0.470 
JVP, (%) 51.9 39.9 0.014 
Rales, (%) 4.1 10.2 0.030 
 
Abbreviations: ACEI: Angiotensin converting enzyme inhibitor, ARB: aldosterone receptor blocker, BMI: body mass index, BP: blood 
pressure, CCB: calcium channel blocker, COPD: chronic obstructive pulmonary disease, eGFR: estimated glomerular filtration rate, 
HFpEF: heart failure with a preserved ejection fraction, MRA: mineral receptor antagonist, NYHA: New York heart association, PVD: 
peripheral vascular disease 
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Table 2. Treatment characteristics during hospitalization  
  ≤50 yrs >50 yrs p-value 
N 121 1912   
Diuretics & diuretic response       
IV loop diuretic dose (mg)       
   Day 2, median (IQR) 80.0 (40.0, 175.0) 80.0 (40.0, 140.0) 0.360 
   Day 3, median (IQR) 80.0 (40.0, 190.0) 76.8 (40.0, 120.0) 0.024 
   Day 4, median (IQR) 63.8 (0.0, 120.0) 40.0 (0.0, 100.0) 0.019 
Total diuretic dose (mg)       
   through Day 2, median (IQR) 170.0 (100.0, 260.0) 220.0 (160.0, 360.0) 0.110 
   through Day 3, median (IQR) 267.5 (150.0, 350.0) 355.0 (240.0, 546.3) 0.260 
   through Day 4, median (IQR) 220.0 (200.0, 420.0) 450.0 (320.0, 720.0) 0.065 
Total IV diuretics (mg)       
   through Day 2, median (IQR) 200.0 (100.0, 400.0) 160.0 (120.0, 300.0) 0.036 
   through Day 3, median (IQR) 340.0 (200.0, 610.0) 260.0 (179.7, 480.0) 0.005 
Total loop diuretics (mg) Day 7 or discharge, 
median (IQR) 320.0 (120.0, 780.0) 280.0 (130.0, 560.0) 0.160 
Weight (kg)       
23 
   Day1, mean ± SD 93.3 ± 29.5 81.2 ± 18.5 <0.001 
   Day4, mean ± SD 89.1 ± 27.9 78.3 ± 17.7 <0.001 
Δweight (kg)       
   Day1 to 2, mean ± SD -1.5 ± 2.4 -1.4 ± 1.9 0.600 
   Day1 to 3, mean ± SD -2.7 ± 3.0 -2.3 ± 2.5 0.051 
   Day1 to 4, mean ± SD -3.4 ± 3.8 -2.8 ± 2.9 0.048 
Diuretic response (kg)        
   Day2, mean ± SD -0.8 ± 0.9 -0.7 ± 0.9 0.420 
   Day3, mean ± SD -0.6 ± 0.6 -0.5 ± 0.7 0.600 
   Day4, mean ± SD -0.5 ± 0.5 -0.4 ± 0.5 0.640 
Patients without diuretic response, % 25.0 18.7 0.750 
IV Diuretic response (kg)        
   Day2, mean ± SD -0.9 ± 1.2 -0.9 ± 1.4   0.270 
   Day3, mean ± SD -0.8 ± 0.8 -0.6 ± 0.9   0.130 
   Day4, mean ± SD -0.6 ± 0.8 -0.5 ± 0.7   0.450 
In-hospital outcome       
Worsening renal function, % 5.8 15.3 0.004 
Discharged alive, % 98.3 95.5 0.130 
24 
Days of Initial Hospital Stay, median (IQR) 7.0 (5.0, 13.0) 8.0 (6.0, 14.0) 0.140 
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Table 3. Individual components of the primary endpoint, rehospitalization details and mode of death 
 
  ≤50 >50 p-value 
 (n=121) (n=1912)  
Primary endpoint  
  
0.100  
Treatment success*, %  47.1 38.6   
Patient unchanged†, %  38.0 39.9   
Treatment failure (any 1 of the following) through day 7, %  14.9 21.5   
     Death‡, % 0.0 1.9 0.120 
     Readmission for heart failure, % 2.5 0.3 <0.001 
     In-hospital worsening heart failure§, % 9.1 9.5 0.890 
     Persistent renal impairment| |, % 5.9 13.3 0.020 
     Serum creatinine increase of ≥0.3 mg/dL, % 5.9 12.9 0.027 
     Hemofiltration or dialysis, % 0.8 0.6 0.730 
Rehospitalization through Day 60       
Frequency, median (IQR) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0) 0.390 
Days, mean ± SD 3.2 ± 7.4 2.7 ± 6.1 0.400 
Days alive and out of hospital, mean ± SD 44.4 ± 15.3 42.4 ± 16.5 0.200 
Rehospitalization or death, %  33.9 33.2 0.880 
26 
Rehospitalization (cardiovascular or renal) or death, % 28.9 28.6 0.940 
Rehospitalization (heart failure) or death, % 23.1 21.5 0.670 
Death through Day 180       
Death, % 9.9 18.1 0.021 
Causes of death     0.450 
     Heart failure / pump failure, % 66.7 51.6   
     Sudden death, % 0.0 12.1   
     Cardiac (no-heart failure), % 0.0 7.4   
     Vascular, % 0.0 8.4   
     Sepsis/pneumonia, % 0.0 8.4   
     Other non-cardiovascular, % 16.7 8.9   
     Unknown, % 16.7 3.2   
 
Table Legend: 
 
*, Treatment success (determined at 24 and 48 hours after the start of study drug [Day 2 and 3] or the day of discharge, if earlier):  
Dyspnea reported by the patient using a 7-point Likert scale as moderately or markedly better compared with study start, AND Not a treatment failure 
†, Patient unchanged: Neither treatment success nor treatment failure 
‡, Death or readmission for heart failure any time through Day 7 
§, Worsening symptoms and/or signs of heart failure occurring >24 hours after the start of study drug to Day 7 or discharge, whichever occurs first, such that 
there is a need for any one of the following types of ‘‘rescue therapy’’: an increase in the dose or reinstitution of IV loop diuretic therapy, or initiation of oral 
metolazone or IV chlorothiazide as accompanying therapy to loop diuretics initiation of ultrafiltration initiation of IV positive inotropes, vasopressors, or IV 
vasodilators initiation of mechanical ventilatory (including BiPAP or CPAP) or circulatory support 
| |, Persistent renal impairment as defined by a serum creatinine increase of ≥0.3 mg/dL (25.5 umol/L) from randomization to Day 7, confirmed at Day 14, or 
the initiation of hemofiltration or dialysis through Day 7 
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Table 4. Baseline biomarkers across age groups  
 
Age (years) ≤50 yrs >50 yrs p-value 
N 121 1912   
Inflammation       
CRP (ng/ml) 13.0 (8.5, 25.1) 14.1 (7.4, 27.9) 0.910 
D-Dimer (ng/ml) 152.5 (90.6, 273.1) 163.3 (90.6, 355.8) 0.180 
GDF-15 (ng/ml) 4.6 (2.6, 6.3) 4.5 (3.1, 6.3) 0.510 
Interleukin 6 (pg/ml) 9.4 (5.2, 14.7) 11.2 (6.6, 21.2) 0.029 
Pentraxin-3 (ng/ml) 3.9 (2.6, 6.9) 4.4 (2.9, 7.0) 0.230 
Procalcitonin (ng/ml) 0.0 (0.0, 0.1) 0.0 (0.0, 0.0) 0.520 
PIGR (ng/ml) 280.8 (204.4, 391.7) 405.8 (266.4, 671.9) <0.001 
PSAP-B (ng/ml) 35.9 (26.8, 51.0) 38.6 (28.5, 53.6) 0.100 
RAGE (ng/ml) 4.8 (3.6, 7.2) 5.0 (3.6, 6.7) 0.900 
TNF-R1a (ng/ml) 2.3 (1.7, 3.5) 3.3 (2.3, 4.8) <0.001 
WAP4C (ng/ml) 17.4 (8.7, 31.0) 28.4 (14.8, 52.9) <0.001 
Oxidative stress       
MPO (ng/ml) 37.4 (16.4, 67.4) 34.0 (18.3, 71.1) 0.990 
Remodeling       
28 
Syndecan-1 (ng/ml) 8.3 (6.9, 10.1) 8.4 (7.0, 10.1) 0.510 
Periostin (ng/ml) 6.3 (3.3, 9.8) 5.5 (3.2, 8.9) 0.310 
Galectin-3 (ng/ml) 30.1 (25.3, 44.2) 36.5 (27.9, 49.0) 0.003 
Osteopontin (ng/ml) 109.3 (73.9, 155.3) 112.3 (78.5, 168.1) 0.450 
Cardiac Stretch       
BNP (pg/ml) 522.8 (348.2, 930.2) 441.7 (253.8, 796.9) 0.050 
ST-2 (ng/ml) 4.5 (1.6, 8.0) 3.5 (1.0, 8.0) 0.210 
Troponin I (pg/ml) 7.4 (4.6, 14.5) 10.7 (5.6, 23.5) 0.004 
Angiogenesis       
VEGFR (ng/ml) 0.5 (0.3, 0.8) 0.4 (0.2, 0.6) <0.001 
Angiogenin (ng/ml) 2299.5 (1451.5, 3117.1) 1833.0 (1232.0, 2761.3) 0.030 
Mesothelin (ng/ml) 80.5 (68.5, 92.3) 87.2 (74.7, 101.3) 0.001 
Neuropilin (ng/ml) 12.9 (9.1, 19.2) 12.5 (8.2, 17.5) 0.370 
proADM (ng/ml) 2.7 (1.6, 4.6) 2.8 (1.5, 4.8) 0.730 
NTpro-CNP (ng/ml) 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.036 
Endothelin 1 (pg/ml) 7.2 (5.4, 9.6) 6.8 (4.9, 9.2) 0.140 
Troy (ng/ml) 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) <0.001 
Arteriosclerosis       
29 
ESAM (ng/ml) 59.5 (55.6, 63.8) 62.2 (56.4, 69.8) 0.002 
LTBR (ng/ml) 0.3 (0.2, 0.5) 0.4 (0.3, 0.6) <0.001 
Renal function       
NGAL (ng/ml) 57.1 (39.8, 92.0) 83.9 (54.2, 137.6) <0.001 
KIM 1 (pg/ml) 206.7 (108.0, 340.2) 299.5 (186.8, 489.6) <0.001 
BUN (mg/dl) 24.0 (19.0, 37.0) 30.0 (22.0, 41.0) <0.001 
 
Abbreviations: CRP: C-reactive protein, ESAM: endothelial cell-selective adhesion molecule, ET-1: endothelin-1,  GDF-15: growth differentiation factor 15; 
IL-6: interleukin-6, KIM-1: kidney injury molecule 1, LTBR: lymphotoxin beta receptor,   proADM: pro-adr-enomedullin, NGAL: neutrophil Gelatinase-
associated Lipocalin, NT-proBNP: N-terminal pro-brain natriuretic peptide, NT-proCNP:N-terminal pro-C-type natriuretic peptide, PCT: procalcitonin, PIGR: 
Polymeric immunoglobulin receptor, PSAP-B: Prosaposin B, RAGE: Receptor for advanced  glycation end product, sST-2: Soluble ST-2, TNF-R1: tumor 
necrosis factor alpha receptor 1, cTnI: cardiac troponin I, VEGFR-1: vascular endothelial growth receptor 1A, WAP-4C: WAP Four-Disulphide Core Domain 
Protein HE 
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Figure 1: Changes of medication during hospitalization 
 
 
 
 
 
 
